SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Pachman LM. Juvenile dermatomyositis: a clinical overview [review]. Pediatr Rev 1990; 12: 11725.
  • 2
    Hochberg MC, Lopez-Acuna D, Gittelsohn AM. Mortality from polymyositis and dermatomyositis in the United States, 1968–1978. Arthritis Rheum 1983; 26: 146571.
  • 3
    Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983; 103: 8828.
  • 4
    Huber AM, Lang B, LeBlanc CM, Birdi N, Bolaria RK, Malleson P, et al. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. Arthritis Rheum 2000; 43: 5419.
  • 5
    Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr 1984; 105: 399408.
  • 6
    Miller LC, Michael AF, Kim Y. Childhood dermatomyositis: clinical course and long-term follow-up. Clin Pediatr (Phila) 1987; 26: 5616.
  • 7
    Stringer E, Feldman BM. Advances in the treatment of juvenile dermatomyositis [review]. Curr Opin Rheumatol 2006; 18: 5036.
  • 8
    Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005; 52: 35708.
  • 9
    Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol 2000; 27: 2498503.
  • 10
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts) [review]. N Engl J Med 1975; 292: 3447.
  • 11
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts) [review]. N Engl J Med 1975; 292: 4037.
  • 12
    Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology (Oxford) 2004; 43: 4916.
  • 13
    Huber AM, Feldman BM, Rennebohm RM, Hicks JE, Lindsley CB, Perez MD, et al. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum 2004; 50: 1595603.
  • 14
    Huber AM, Hicks JE, Lachenbruch PA, Perez MD, Zemel LS, Rennebohm RM, et al, for the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. J Rheumatol 2001; 28: 110611.
  • 15
    Kendall F. Muscles: testing and function. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 1993.
  • 16
    Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006; 148: 24753.
  • 17
    McCann LJ, Juggins AD, Maillard SM, Wedderburn LR, Davidson JE, Murray KJ, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland): clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford) 2006; 45: 125560.
  • 18
    Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al. US incidence of juvenile dermatomyositis, 1995–1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003; 49: 3005.
  • 19
    Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al. Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003; 42: 14529.
  • 20
    Huber A, Dugan E, Lachenbruch PA, Feldman BM, Perez M, Zemel L, et al. Reliability of the Cutaneous Assessment Tool (CAT) in juvenile dermatomyositis (JDM) [abstract]. Arthritis Rheum 2005; 52 Suppl 9: S314.
  • 21
    Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002; 47: 50511.
  • 22
    Sallum AM, Kiss MH, Sachetti S, Resende MB, Moutinho KC, Carvalho Mde S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuropsiquiatr 2002; 60: 88999.
  • 23
    Tabarki B, Ponsot G, Prieur AM, Tardieu M. Childhood dermatomyositis: clinical course of 36 patients treated with low doses of corticosteroids. Eur J Paediatr Neurol 1998; 2: 20511.
  • 24
    Smith RL, Sundberg J, Shamiyah E, Dyer A, Pachman LM. Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops. J Rheumatol 2004; 31: 16449.
  • 25
    Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003; 62: 4449.
  • 26
    Duffy CM, Laxer RM, Lee P, Ramsay C, Fritzler M, Silverman ED. Raynaud syndrome in childhood. J Pediatr 1989; 114: 738.
  • 27
    Spencer-Green G, Crowe WE, Levinson JE. Nailfold capillary abnormalities and clinical outcome in childhood dermatomyositis. Arthritis Rheum 1982; 25: 9548.
  • 28
    Taieb A, Guichard C, Salamon R, Maleville J. Prognosis in juvenile dermatopolymyositis: a cooperative retrospective study of 70 cases. Pediatr Dermatol 1985; 2: 27581.
  • 29
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003; 49: 715.